Dr. Sylvain Fleury has 25 years of experience in infectious diseases, involving pre-clinical & clinical development. He did a Ph.D. in Immunology and Microbiology at the Clinical Research Institute of Montreal (Canada), in collaboration with Genentech (California) and Columbia Hospital (New-York). He did a post-doc at the NIAID/NIH in (Bethesda, USA) from 1993-1996 prior moving in Switzerland at the Beaumont Hospital (CHUV-Lausanne) in 1997. He was involved in various clinical trials, investigating the benefit of antiviral tri-therapies on the disease course and the immune system regeneration, in collaboration with Roche. From 2000 to 2004, Dr. Fleury worked at the Cardiology department (CHUV) for developing gene therapies with adenoviral and lentiviral vectors expressing chemokine antagonists for preventing heart allorejection. Dr. Fleury became the Chief Scientific Officer of MYMETICS Corporation in 2003, developing virosome-based prophylactic vaccines for blocking early events of pathogen transmission and infection (pipeline: HIV, malaria, RSV, influenza), with a high interest in mucosal immunity induction.